Personalized Pharmaceutical Systems said that it has sold the Angioedema Clinical Prediction Guide to ViroPharma Inc. (VPHM).
PPS is a clinical trial enrichment and market differentiation company, which has developed advanced technology in phenomics to help drug companies identify the correct patients for their drugs, and as a result help patients get the right drug the first time.
Through the use of its phenomic technology, PPS developed the Angioedema Clinical Prediction Guide to help emergency room physicians quickly differentiate amongst different types of angioedema that can be life-threatening.
For comments and feedback: editorial@rttnews.com